arctigenin has been researched along with Inflammatory Bowel Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, Y; Fang, YL; Lv, CJ; Qiao, SM; Tao, Y; Wei, ZF; Xia, YF; Yue, MF; Yun, XM | 1 |
| Dai, Y; Fang, Y; Lv, C; Qiao, S; Tao, Y; Wei, Z; Xia, Y; Yue, M; Yun, X | 1 |
2 other study(ies) available for arctigenin and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Phytoestrogen arctigenin preserves the mucus barrier in inflammatory bowel diseases by inhibiting goblet cell apoptosis via the ERβ/TRIM21/PHB1 pathway.
Topics: Animals; Apoptosis; Colitis; Estrogen Receptor beta; Furans; Goblet Cells; Inflammatory Bowel Diseases; Lignans; Mice; Mice, Inbred C57BL; Mucus; Phytoestrogens; Prohibitins | 2022 |
Pharmacological activation of ERβ by arctigenin maintains the integrity of intestinal epithelial barrier in inflammatory bowel diseases.
Topics: Animals; Caco-2 Cells; Estrogen Receptor beta; Female; Furans; HT29 Cells; Humans; Inflammatory Bowel Diseases; Interleukin-1beta; Intestinal Mucosa; Lignans; Mice; Mice, Inbred BALB C; Mutation, Missense; Myosin-Light-Chain Kinase; Signal Transduction; Tumor Necrosis Factor-alpha | 2020 |